New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini(University of Pavia), Giampaolo Merlini(University of Pavia), Efstathios Kastritis(AOL (United States)), Shaji Kumar(Mayo Clinic in Arizona), Arnaud Jaccard(AOL (United States)), Philip N. Hawkins(The Royal Free Hospital), Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Angela Dispenzieri(WinnMed), Stefan Schönland(AOL (United States)), Ashutosh Wechalekar(Boston University), Catherine Klersy(AOL (United States)), Ute Hegenbart(City Of Hope National Medical Center), Raymond L. Comenzo(Memorial Sloan Kettering Cancer Center), Morie A. Gertz(Mayo Clinic in Arizona)
Cited by 965
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k